Pharma Pulse 12/17/24: Analyzing Top Biopharmaceuticals Performance Metrics, Ketamine Treatment Shows Promise & more

Trade & Channel Strategies 2024: Industry Audit—Analyzing Top Biopharmaceuticals Performance Metrics

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the breakout session at Trade & Channel Strategies in Philadelphia.

Ketamine Treatment Shows Promise for Treatment-Resistant Depression

Ketamine intravenous treatment (KIT) may be more effective than traditional medication management for those with treatment resistant depression (TRD), helping reduce symptoms and improve responses to treatment, according to new a study published in the 2025 issue of Psychiatry Research.

Pizza Buffets, Fishing Boats and Bathroom Lines Are All Getting an AI Makeover. Thank One Man.

Entrepreneur Eliot Horowitz, who founded $22 billion database company MongoDB, is betting on artificial intelligence in the physical world.

Biocodex Strengthens Supply Chain Resilience with Kinaxis

Biocodex has partnered with Kinaxis^® Inc. to modernize and optimize its processes. Through this collaboration, Biocodex aims to achieve greater forecast accuracy, simplify the management of regulatory challenges, and enhance resilience against disruptions.

Katie Rapp on LinkedIn

Great article with good ideas for 2025!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs